185629-31-6Relevant articles and documents
Synthesis route and preparation method of 3-fluorine-4-nitrobenzaldehyde
-
Paragraph 0004; 0011-0012; 0016-0017, (2021/01/28)
The invention discloses a new synthetic route of 3-fluorine-4-nitrobenzaldehyde and a preparation method thereof. The preparation method comprises the following steps: adding 3-fluorine-4-nitrobenzoicacid and an acidic catalyst into an organic solvent methanol, stirring at 60 to 80 DEG C for 5 to 12 hours, and carrying out after-treatment to obtain a solid intermediate product 2; adding the intermediate product 2 into an organic solvent II, adding sodium borohydride while uniformly stirring at 0 DEG C, stirring for 0.5 to 1h at 0 DEG C, slowly heating to 60 DEG C, stirring for 2 to 6h, stopping stirring, and carrying out post-treatment to obtain an intermediate product 3; and adding the intermediate product 3 and an oxidant III into an organic solvent IV, heating and refluxing for 3 to 10hours, cooling to 20 to 30 DEG C after the reaction is finished, and carrying out post-treatment on the reaction solution to obtain the product 3-fluorine-4-nitrobenzaldehyde. According to the methoddisclosed by the invention, sodium borohydride which is safe and easy to treat is adopted to replace high-activity ultralow-temperature anhydrous oxygen diisobutyl aluminum hydride for reduction reaction, so that a relatively good effect is achieved, and the compound 3-fluorine-4-nitrobenzaldehyde is safely and efficiently synthesized. The method is simple, the requirements of production equipment are reduced, the cost is controlled, and the method is suitable for industrial production.
TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION
-
Page/Page column 71, (2020/03/23)
The present invention relates to linker molecules of formula (1), X-Tb-Va-U-Y-Z (1) and a method for purifying peptides using said linker molecules. The linker molecule can be coupled to a purification resin via the moiety X and to a
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors
Cao, Danyan,Chen, Danqi,Chen, Lin,Damaneh, Mohammadali Soleimani,Hu, Jianping,Huan, Xia-Juan,Li, Jian,Li, Yanlian,Lv, Kaikai,Meng, Tao,Miao, Ze-Hong,Qin, Lihuai,Shen, Jingkang,Song, Shan-Shan,Tian, Chang-Qing,Wang, Xin,Wang, Ying-Qing,Xiong, Bing,Yu, Ting
, (2019/10/08)
BRD4 has recently emerged as a promising drug target. Therefore, identifying novel inhibitors with distinct properties could enrich their use in anticancer treatment. Guided by the cocrystal structure of hit compound 4 harboring a five-membered-ring linker motif, we quickly identified lead compound 7, which exhibited good antitumor effects in an MM.1S xenograft model by oral administration. Encouraged by its high potency and interesting scaffold, we performed further lead optimization to generate a novel potent series of bromodomain and extra-terminal (BET) inhibitors with a (1,2,4-triazol-5-yl)-3,4-dihydroquinoxalin-2(1H)-one structure. Among them, compound 19 was found to have the best balance of activity, stability, and antitumor efficacy. After confirming its low brain penetration, we conducted comprehensive preclinical studies, including a multiple-species pharmacokinetics profile, extensive cellular mechanism studies, hERG assay, and in vivo antitumor growth effect testing, and we found that compound 19 is a potential BET protein drug candidate for the treatment of cancer.